🎉 M&A multiples are live!
Check it out!

Nurix Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nurix Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Nurix Therapeutics Overview

About Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.


Founded

2009

HQ

United States of America
Employees

286

Website

nurixtx.com

Financials

LTM Revenue $57.6M

LTM EBITDA -$212M

EV

$228M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nurix Therapeutics Financials

Nurix Therapeutics has a last 12-month revenue of $57.6M and a last 12-month EBITDA of -$212M.

In the most recent fiscal year, Nurix Therapeutics achieved revenue of $54.5M and an EBITDA of -$197M.

Nurix Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nurix Therapeutics valuation multiples based on analyst estimates

Nurix Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $77.0M $54.5M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$141M -$197M XXX XXX XXX
EBITDA Margin -184% -360% XXX XXX XXX
Net Profit -$180M -$144M XXX XXX XXX
Net Margin -234% -264% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nurix Therapeutics Stock Performance

As of April 15, 2025, Nurix Therapeutics's stock price is $10.

Nurix Therapeutics has current market cap of $751M, and EV of $228M.

See Nurix Therapeutics trading valuation data

Nurix Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$228M $751M XXX XXX XXX XXX $-2.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nurix Therapeutics Valuation Multiples

As of April 15, 2025, Nurix Therapeutics has market cap of $751M and EV of $228M.

Nurix Therapeutics's trades at 4.0x LTM EV/Revenue multiple, and -1.1x LTM EBITDA.

Analysts estimate Nurix Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nurix Therapeutics and 10K+ public comps

Nurix Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $228M XXX XXX XXX
EV/Revenue 4.1x XXX XXX XXX
EV/EBITDA -1.1x XXX XXX XXX
P/E -3.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nurix Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nurix Therapeutics Valuation Multiples

Nurix Therapeutics's NTM/LTM revenue growth is 11%

Nurix Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Nurix Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nurix Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nurix Therapeutics and other 10K+ public comps

Nurix Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -29% XXX XXX XXX XXX
EBITDA Margin -363% XXX XXX XXX XXX
EBITDA Growth 39% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -352% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 84% XXX XXX XXX XXX
R&D Expenses to Revenue 406% XXX XXX XXX XXX
Opex to Revenue 491% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nurix Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nurix Therapeutics M&A and Investment Activity

Nurix Therapeutics acquired  XXX companies to date.

Last acquisition by Nurix Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nurix Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nurix Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nurix Therapeutics

When was Nurix Therapeutics founded? Nurix Therapeutics was founded in 2009.
Where is Nurix Therapeutics headquartered? Nurix Therapeutics is headquartered in United States of America.
How many employees does Nurix Therapeutics have? As of today, Nurix Therapeutics has 286 employees.
Who is the CEO of Nurix Therapeutics? Nurix Therapeutics's CEO is Dr. Arthur T. Sands, M.D.,PhD.
Is Nurix Therapeutics publicy listed? Yes, Nurix Therapeutics is a public company listed on NAS.
What is the stock symbol of Nurix Therapeutics? Nurix Therapeutics trades under NRIX ticker.
When did Nurix Therapeutics go public? Nurix Therapeutics went public in 2020.
Who are competitors of Nurix Therapeutics? Similar companies to Nurix Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Nurix Therapeutics? Nurix Therapeutics's current market cap is $751M
What is the current revenue of Nurix Therapeutics? Nurix Therapeutics's last 12-month revenue is $57.6M.
What is the current EBITDA of Nurix Therapeutics? Nurix Therapeutics's last 12-month EBITDA is -$212M.
What is the current EV/Revenue multiple of Nurix Therapeutics? Current revenue multiple of Nurix Therapeutics is 4.0x.
What is the current EV/EBITDA multiple of Nurix Therapeutics? Current EBITDA multiple of Nurix Therapeutics is -1.1x.
What is the current revenue growth of Nurix Therapeutics? Nurix Therapeutics revenue growth between 2023 and 2024 was -29%.
Is Nurix Therapeutics profitable? Yes, Nurix Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.